Journal
JOURNAL OF MEDICINAL CHEMISTRY
Volume 60, Issue 18, Pages 7617-7635Publisher
AMER CHEMICAL SOC
DOI: 10.1021/acs.jmedchem.6b01672
Keywords
-
Categories
Funding
- National Natural Science Foundation of China [81273378, 21372261, 81673305, 81602960]
- Jiangsu Province Funds for Distinguished Young Scientists [BK20160033]
- Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD)
- Program for New Century Excellent Talents in University [NCET-13-1033]
- Startup Funding for Introduced Talents of Nanjing Medical University [KY109RC1602]
- Jiangsu Shuang Chuang team
Ask authors/readers for more resources
The increasing understanding of the role of nitric oxide (NO) in cancer biology has generated significant progress in the use of NO donor-based therapy to fight cancer. These advances strongly suggest the potential adoption of NO donor-based therapy in clinical practice, and this has been supported by several clinical studies in the past decade. In this review, we first highlight several types of important NO donors, including recently developed NO donors bearing a dinitroazetidine skeleton, represented by RRx-001, with potential utility in cancer therapy. Special emphasis is then given to the combination of NO donor(s) with other therapies to achieve synergy and to the hybridization of NO donor(s) with an anticancer drug/agent/fragment to enhance the activity or specificity or to reduce toxicity. In addition, we briefly describe inducible NO synthase gene therapy and nanotechnology, which have recently entered the field of NO donor therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available